Clearmind Medicine Inc Common Shares

Yahoo Finance • 8 days ago

Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico

Vancouver, Canada, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived t... Full story

Yahoo Finance • last year

Clearmind Medicine Closes US$2.25 Million Public Offering

Tel Aviv, Israel / Vancouver, Canada, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and development of novel psychedelic-derive... Full story

Yahoo Finance • last year

Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering

Tel Aviv, Israel / Vancouver, Canada, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and development of novel psychedelic-derive... Full story

Yahoo Finance • 2 years ago

Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

The conference will stream live on Monday, June 12, at 10:00 AM EST Tel Aviv, Israel / Vancouver, Canada, June 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a... Full story

Yahoo Finance • 2 years ago

Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial

Tel Aviv, Israel / Vancouver, Canada, May 02, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on discovery and development of novel psyched... Full story

Yahoo Finance • 2 years ago

Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression

The application is for a novel psychedelic-based combination, of Clearmind's MEAI and SciSparc'sCannamide™ Tel Aviv, Israel / Vancouver, Canada, April 21, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE... Full story

Yahoo Finance • 2 years ago

SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression

The application refers to a novel psychedelic-based combination of Clearmind's MEAI and SciSparc's Cannamide™ TEL AVIV, Israel, April 21, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clini... Full story

Yahoo Finance • 2 years ago

Clearmind Medicine Closes US$3.5 Million Public Offering

Tel Aviv, Israel / Vancouver, Canada, April 06, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and development of novel psychedelic-derive... Full story

Yahoo Finance • 2 years ago

Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering

Tel Aviv, Israel / Vancouver, Canada, April 04, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and development of novel psychedelic-deriv... Full story